Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7798 PET Study in Healthy Participants and Crohn's Disease
NCT06053424Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of azd7798 in Crohn's disease (6 arms), sponsored by AstraZeneca. Primary endpoints: Percentage Change in Small Bowel Partition Coefficient (Kp) From Baseline (PET1 Visit) to PET2 Visit at Day 2 and Percentage Change in Small Bowel Partition Coefficient (Kp) From Baseline (PET1 Visit) to PET3 Visit at Day 28. Started Sep 2023; status: completed.
02
Drugs
azd7798
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06053424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06053424.